Sunday, 26 August 2012

Autism and immune dysfunction: don't forget your roots?

You're going to have to humour me a little with this post based on this opinion piece by Moises Velasquez-Manoff which appeared in the New York Times recently. I normally try and stick to discussing peer-reviewed published research on this blog but given the content of this article titled: "An immune disorder at the root of autism" (no question mark by the way), I couldn't resist having a more detailed look at some of the discussions which do include reference to some peer-reviewed research.

So what does it say?


I don't think I've missed anything out. The main message seems to be that increasing autism rates seem to be correlated with population increases in hygiene and less exposure to bacterial and viral infections and the knock-on effects to immune function. Actually this is not the first time that Mr Velasquez-Manoff has talked about some of these concepts are per this article from 2008 on worm therapy for inflammatory bowel disease (IBD) which is also the topic of his book (no plug intended).

There is no doubt that this is an interesting article which has some degree of support (published scientific support) behind elements of it. Outside of the journalist flair that accompanies the article - "perhaps one-third, and very likely more — looks like a type of inflammatory disease" (evidence please!) autism and immune function is an area of great research interest and speculation. Still however questions remain about how widespread immune dysfunction is in autism, the chicken or egg question of which came first: autism or immune dysfunction, and indeed whether immunological issues are a core part of autism, some cases of autism, or perhaps just another face of comorbidity.

[Update 31 August 2012: In response to some discussion about the lack of scientific references accompanying the article by Moises Velasquez-Manoff, the author has posted a reference source list on his website].

----------

Patterson P. Maternal infection and immune involvement in autism. Trends in Molecular Medicine. 2011; 17: 389-394.

Stick with me kid: adhesion molecules and autism

Spider web by Luc Viatour / www.Lucnix.be
A paper by Charity Onore and colleagues* from the MIND Institute caught my eye quite recently. The topic was adhesion, and in particular cell adhesion related to immune function; and an analysis of some of the primary players in this sticky process such as the selectins and other interesting molecules including CD31 otherwise known as PECAM-1 (see here for an explanation) in relation to autism. From the outset, I should clarify that this is not a post on the neuronal cell adhesion research that has been undertaken on autism (see here). As if I would know where to start on that research area...

Regular readers of this blog might already understand that I have a continued interested in the output from the MIND Institute with autism in mind, much of which has been summarised in another paper from Dr Onore** on the role of the immune system in cases of autism. Indeed just reading the abstract to this summary paper makes me further realise how complex and 'real' the immune system findings are to autism - some cases of autism. These are not just funny abbreviations like IL-6 or INF but very real elements to what is a very complicated condition. An interesting opinion piece arrives at similar conclusions.

Anyway, back to the topic/paper at hand, cell adhesion, and probably best if I try and translate a few of the concepts outlined in the recent paper as well as summarising what was found, just so you know how the findings might fit in.

  • 'leukocyte transendothelial migration' basically refers to the process of getting leukocytes (white blood cells) to the site of infection or injury. If you can bear some pretty heavy biochemistry, this paper by Liu and colleagues*** (full-text) offers quite a detailed description of what's potentially involved in the process.
  • 'Levels of sPECAM-1 and sP-selectin were significantly reduced in the ASD group'. The selectins are kinda the first response in recruiting leukocytes to where they're needed. From what I can gather, they 'tether' white blood cells (leukocytes) to the endothelial cells to facilitate rolling to the site of injury and inflammation (see here). I suppose it's kinda like a velcro response although perhaps not so permanent (see here). Lower levels of [plasma soluble] sP-selectin might indicate some issue with the ability to perform these adhesive duties bearing in mind that the other selectins, L-selectin and E-selectin also play an important role. Given the link between elevations of sP-selectin as a marker for platelet / endothelial activation (among other things), one has to suggest that these results are perhaps reflective of hypo-activation compared with controls. Similar findings have been reported previously**** (full-text).
  • Lower levels of platelet endothelial adhesion molecule-1 (PECAM-1) (see here for a good overview) were also reported. PECAM-1 seems to perform a similar role with regards to adhesion. Interestingly, this is again not the first time that lower levels of PECAM-1 have been reported in cases of autism*****. 
  • "Soluble PECAM-1 levels were negatively associated with repetitive behavior and abnormal brain growth in children with ASD (p = .03)". In other words, low levels of PECAM-1 were linked to elevated levels of repetitive behaviours and unusual head growth (again as per the Tsuchuiya findings).

I can't claim to be a world's expert on this area of autism research so won't go to far further into the possible meaning. The authors conclude that these adhesion molecules "modulate the permeability and signaling at the blood-brain barrier". That is true as per reviews like this one from Kalinowska & Losy****** on PECAM-1 and neuroinflammation. Unless I'm reading this wrong, the only issue being that elevated levels of PECAM-1 seem to be related to such issues; the current results were kinda sailing against that tide at least in their cohort as a group.

Taken at face value, these results may suggest that the various ways and means that the body deals with inflammation may be perturbed in some cases of autism. Without actually knowing whether inflammation (acute or chronic) was present in the described cases of the current study, it is slightly difficult to make too much of the findings as they stand. Reiterating that the involvement of the immune system in cases of autism is far from simple - some say presentation of under-activation (as per this article on the immunoglobulins by the MIND Institute) others say over-activation (see here) - one has to be cautious about making sweeping generalisations. Realising also that the immune system is not just one system, as per the innate vs. adaptive classifications.

A final note. One added bonus to the current paper was the relationship with the Autism Phenome Project (APP) which very importantly realises that autism is an umbrella term to describe lots and lots of different presentations; not necessarily all the same thing however in terms of aetiology or trajectory (see the 'bloomers' post). Indeed based on the previous results reported for the APP looking at brain enlargement and regression in autism (see here), there is perhaps some overlap in participants taking part in the current study also.

To finish, the sad news of the death of a true icon of the age, Neil Armstrong, brings to mind an apt song, Man on the Moon by REM. Truly one small step, one giant leap.

----------

* Onore CE. et al. Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder. Biological Psychiatry. June 2012.

** Onore CE. et al. The role of immune dysfunction in the pathophysiology of autism. Brain, Behavior & Immunity. 2012; 36: 383-392.

*** Liu Y. et al. Regulation of leukocyte transmigration: cell surface interactions and signaling events. Journal of Immunology. 2004; 172: 7-13.

**** Iwata Y. et al. Serum levels of P-selectin in men with high-functioning autism. British Journal of Psychiatry. 2008; 193: 338-339.

**** Tsuchuiya KJ. et al. Decreased serum levels of platelet-endothelial adhesion molecule (PECAM-1) in subjects with high-functioning autism: a negative correlation with head circumference at birth. Biological Psychiatry. 2007; 62: 1056-1058.

***** Kalinowska A. & Losy J. PECAM-1, a key player in neuroinflammation. European Journal of Neurology. 2006; 13: 1284-1290.

----------

ResearchBlogging.org Onore CE, Nordahl CW, Young GS, Van de Water JA, Rogers SJ, & Ashwood P (2012). Levels of Soluble Platelet Endothelial Cell Adhesion Molecule-1 and P-Selectin Are Decreased in Children with Autism Spectrum Disorder. Biological Psychiatry PMID: 22717029

Thursday, 23 August 2012

De novo mutations, older dads and autism (again)

Those with an interest in autism (and/or schizophrenia) will have probably already seen the headlines discussing the study by Augustine Kong and colleagues* on  the rate of de novo genetic mutations and a father's age as being potentially important for conditions like autism and schizophrenia. For those like me who are still struggling with all things mutation, quite a nice summary of the current research is offered in this Nature commentary accompanying the study.

I'm going to briefly focus on the potential implications specifically for autism in this post, accepting that (a) de novo mutations have been looked at with schizophrenia in mind (see here) and (b) increasing parental (and grand-parental) age has been linked to an increased risk of schizophrenia (see here).

This is not the first time this year that findings related to de novo mutation and paternal age in relation to autism have surfaced in Nature as discussed in this post. The latest study from Kong and colleagues suggests a few things:

  • The entire genome of 78 families (mum, dad, child) of Icelandic-origin was sequenced.
  • They studied the small genetics changes, SNPs, in and between mums and dads and their children, taking into account the age of the parents. Apparently of the offspring included for study, 44 had received a diagnosis of an autism spectrum disorder and 21 diagnosed with schizophrenia.
  • Their analysis suggested (i) fathers passed on about four times more mutations than mothers, (ii) approximately 2 new mutations were present in children for every year of increase in the father's age at conception - so a father conceiving at 20-years old passed on 25 random mutations compared with a father conceiving at 40-years old who passed on 65 mutations, (iii) mums were reported to pass on about 15 mutations irrespective of age; thought due to the fact that women carry their eggs through life whilst sperm is constantly being produced and therefore potentially subject to the rigours of ageing and environment.

There has, understandably, been some discussion about the implications of this research with regards to autism and more generally about the trend towards couples starting families when they're getting on a bit. Kari Stefansson, lead author on the paper discusses the trend (in Iceland) towards increasing paternal age when conceiving a child - 27.9 years in 1980 to 33 years in 2011 - as a case in point and potentially what implications this may have. That being said, I have to say that I raised a smile when reading about this recent research which suggested that children with older fathers might actually be genetically-programmed to live longer as a function of increasing teleomere length with age in sperm**. I am comparing apples and oranges here but want to show how such things are never straight-forward.

Another debate has also seemingly arisen from the Kong study with regards to the numbers of children with autism being currently diagnosed/estimated, and whether the figures reflect better case ascertainment, etc. or are reflective of a true increase in the numbers of people with autism. To quote from Fred Volkmar (here) "This study provides some of the first solid scientific evidence for a true increase in the condition of autism". Earlier this year I discussed the latest estimates of autism in the United States produced by the CDC and how an estimated 1 in 110 8-year olds with autism became 1 in 88 8-year olds with autism. If accurate, what Dr Volkmar seems to be suggesting is a kind of bridge between the genetics-environment camps which will almost certainly impact on the autism numbers game: older parents, older fathers passing on a greater number of mutations potentially increasing the risk of autism or schizophrenia. I pass no judgement on this proposal by the way.

There are a few final comments to make on this research and the area in general. Regular readers of this blog might already know that I am becoming a bit of a fan of the area of epigentics and the promise that it might hold for conditions like autism. Noting the recent research from Richard Anney and colleagues ("no single SNP shows significant association with ASD or selected phenotypes at a genome-wide level") it's all well and good suggesting that older fathers might increase the risk of autism, but without such details as to which SNPs are consistently and reliably at work, there is likely to be a whole lot more involved in the aetiology of autism than just the structure of the genome. That and my continuing questioning as to whether age is the only factor in causing mutation or whether other environmental 'exposures' might also exert an effect.

Additionally and finally, I've said it before and I'll say it again: autism is not a homogeneous condition. We might talk about autism as being diagnostically homogeneous insofar as a person presents with this triad (soon to be dyad) of symptoms and the autism diagnosis box is ticked, but symptom onset and presentation varies from person to person (endophenotype to endophenotype?) and is further complicated by elevated risk for various comorbidity, psychological, cognitive and also more somatic comorbidity. I see nothing in the current research that rules out the possibility that more mutations passed to offspring as a result of older dads might not also be tied into an increased risk for other things (autoimmune features and conditions, epilepsy, learning disability, depression, anxiety, etc., etc.). Until we can, with some degree of confidence, peel back the diagnostic and risk layers, this issue will be in the background of any autism research.

Don't get me wrong, I am very interesting in the latest results from Kong and the now replicated findings of advancing paternal age and risk in some cases of autism. I do however believe that within the context of all the other research published and on-going in autism, this might be but one small piece of a much larger puzzle on aetiology and underlying pathology.

To finish, Jim Morrison has been on my musical radar of late, so how about some Riders on the Storm?

----------

* Kong A. et al. Rate of de novo mutations and the importance of father’s age to disease risk. Nature. 2012; 488: 471-475.

** Eisenberg DTA. et al. Delayed paternal age of reproduction in humans is associated with longer telomeres across two generations of descendants. PNAS. 2012; 109: 10251-10256.

----------

ResearchBlogging.org Augustine Kong, Michael L. Frigge, Gisli Masson, Soren Besenbacher, Patrick Sulem, Gisli Magnusson, Sigurjon A. Gudjonsson, Asgeir Sigurdsson, Aslaug Jonasdottir, Adalbjorg Jonasdottir, Wendy S. W. Wong, Gunnar Sigurdsson, G. Bragi Walters, Stacy Steinberg, Hannes Helgason, Gudmar Thorleifsson, Daniel F. Gudbjartsson, Agnar Helgason, Olafur Th. Magnusson,, Unnur Thorsteinsdottir, & Kari Stefansson (2012). Rate of de novo mutations and the importance of father’s age to disease risk Nature DOI: 10.1038/nature11396

Tuesday, 21 August 2012

Resurrecting XMRV in Chronic Fatigue Syndrome?

The letters X-M-R-V in relation to Chronic Fatigue Syndrome (CFS) have had their fair share of controversy in recent years. For those who don't know about XMRV - xenotropic murine leukemia virus-related virus - there is ample discussion about this topic on the web or you can browse my past posts covering the story here and here. I'm sure that a feature film or TV mini-series will be made eventually about XMRV and CFS including the back-story of Dr Judy Mikovtis and the whole WPI saga. I'll leave you to make up your own film title.

After all the excitement of contamination, missing notebooks and scientific retractions, you'd think this would be a 'leave well alone' area for many researchers not really wanting to get involved, given the career-tarnishing effects it seems to have. It was with some interest therefore that I stumbled across this fairly recent article by Paolucci and colleagues* (full-text) and their findings on XMRV and CFS adding to the mix.

It is a short paper but nevertheless contains some interesting facts which I'll try and summarise:

  • Twelve participants diagnosed with CFS and some 40 controls (including asymptomatic, those confirmed as HIV positive or hepatitis C infection and transplant recipients) were investigated for the presence of XMRV "and polytropic MLV-related provirus". This last bit taps into some now author retracted research published by Lo and colleagues** (full-text).
  • I can't claim to understand all the ins-and-outs of the process for trying to detect XMRV or its friends but PCR was the name of the game, looking for fragments of DNA from the respective viruses.
  • Results: nothing for the control participants when it came to the potential presence of XMRV or its friends. For the CFS participants, in the majority nothing also except in two participants who "were positive for gag PCR and integrase PCR respectively". Further study of positive participant number 1 suggested that "the retrovirus was more closely related to the polytropic MLV rather than to XMRV (identity 100% vs. 96%)". For participant 2, further analysis "confirmed the similarity with the XMRV sequence".
  • Given the methods used by the authors, the contamination issue that overshadowed the previous research were excluded.

I'm not making too much of this paper at the current time given that other contemporary studies have reported no presence of XMRV in cohorts of participants with CFS (see here and here) alongside the relatively small participant group included as part of the Paolucci study. As per my previous reporting of this area of research, detecting such viruses is not by any means an easy task and no doubt there are still gaps in the methodology and science that need patching up. Even with the virus detected, there is a substantial leap to make before one is able to suggest the virus might be 'causative' of CFS or anything else.

What we can perhaps infer from the Paolucci paper is that the XMRV chapter of CFS research history might not be ready for the scientific scrapheap just yet. The big 'final say' study from virus hunter Ian Lipkin - yes, he of the autism and Sutterella research - has, at the time of writing, still not found its way into the peer-reviewed literature as far as I can see despite some signs it would be here already.

So we wait and see...

While waiting perhaps you would like to hear which Disney song currently fills my house. I've got a dream y'know..

----------

* Paolucci S. et al. Xenotropic and polytropic murine leukemia virus-related sequences are not detected in the majority of patients with chronic fatigue syndrome. New Microbiologica. 2012; 35: 341-344.

** Lo SC. et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. PNAS. 2010. 107: 15874-9 [RETRACTED].

---------

ResearchBlogging.org Paolucci S, Piralla A, Zanello C, Minoli L, & Baldanti F (2012). Xenotropic and polytropic murine leukemia virus-related sequences are not detected in the majority of patients with chronic fatigue syndrome. The new microbiologica, 35 (3), 341-4 PMID: 22842604

Monday, 20 August 2012

Autism and microglia

An interesting paper has appeared by Beumer and colleagues* with the grandiose title: The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. It's an intriguing paper linking specific actions of the immune system on brain areas in connection to various conditions including depression and schizophrenia via a biological entity that seems to be gaining some research interest: microglia.

On the basis of this publication I therefore resisted no longer and decided to set off on the voyage of discovery that is a possible role for microglia in cases of autism. Please understand that I undertake this post with some trepidation as my skill set does not readily encompass the hows and whys of microglia, so be at the ready with that rather large pinch of salt.

Quite a good overview of microglia is here by Kettenmann and colleagues** (full-text) alongside some discussion on their 'constant gardening' effect in this piece by Virginia Hughes*** (full-text). Apparently constituting as much as 10% of the cells of the central nervous system, microglia derive from cells of the immune system and activate in response to injury or inflammation. More than that however, there is some emerging evidence that microglia might also play a role in the pruning process which the developing brain undertakes during the early years and perhaps beyond.

With autism specifically in mind, I've already linked in previous posts to an interesting blog piece from Paul Patterson on microglia potentially eating synapses in autism as a consequence of some interesting research suggesting increased microglial activation in some cases of autism****. I draw your attention also to another interesting blog post on the SFARI website which strengthens a possible connection between microglia and a mouse model of Rett syndrome, noting also the controversial issue of bone marrow transplant as a potential route to "generating healthy microglia". I might add that I am not getting too obsessed with stem cells and the such like, but in light of Prof. Patterson's recent paper, one has to keep an open mind.

Other research on microglia and autism:

  • Starting from the early days of the PubMed catalogue on this topic a few familiar names crop up with microglia in mind. Andrew Zimmerman and colleagues***** (he of the 'can you grow out of autism' research) talked about neuroglial activation and neuroinflammation quite a few years ago. They reported "marked activation of microglia" alongside several other inflammatory related findings in the brains of people with autism. Similar follow-up studies from this research group also talked about paradoxical lower levels of quinolinic acid in cerebrospinal fluid which  brings us back to everyone's favourite aromatic amino acid, tryptophan. I'll leave that for now.
  • Propionic acid (PPA), the topic of quite a recent blog post, also gets a look-in with microglia in mind as per the paper by Derek MacFabe and colleagues******. They report that during their 'inject PPA into rodent brain' experiments, increases in activated microglia was one of the effects contributing to the neuroinflammatory process described. Whilst I would love to be able to say this might tie into the short chain fatty acid findings also talked about with PPA and autism in mind (here), it is probably not unexpected that PPA administration so directly and at such quantities would provoke a reaction from microglia given their activation at the first sight of any foreign invaders.
  • Other research speculates on the role of microglia and autism (here, here and here), in some cases speculating on the potential environmental factors which may exacerbate microglial priming. I was also drawn to this paper by Schwarz & Bilbo******* who discuss how gender differences in the colonisation and function of glia may offer some interesting explanations for the gender differences seen in conditions like autism, acknowledging that glia includes more than just microglia.

There is still some way to go with regards to the microglia-autism story but so far the research base could be described as very interesting. Inflammation, as I have said before, seems to be playing many hands in at least some cases of autism. Whilst the chicken-and-egg debate about immune function and autism continues, there is little doubt that for some, immune involvement - whether mediated/described by microglia activation, circulating cytokines or other markers of inflammation and immune over- or -under activation, seems to be a facet of symptom presentation. The puzzle is still far from complete however.

Finally, there is the question about what can be done about over or chronic activation of microglia. Reiterating my caveat about not giving medical advice or anything approximating such advice and aside from the bone marrow transplant data already touched upon, I was interested to read the various literature on the effect of administration of the tetracycline antibiotic, minocycline on microglial activation as per studies likes this one and this one (both full-text). Accepting that certain antibiotics might be a bit of a double-edged sword for some cases of autism (see this post) as well as such compounds having other, more recognised antimicrobial action - potentially important in some cases of autism - it does make me wonder whether targeting such interventions at activated microglia at a critical time might be a research area worth investing in.

To finish, I'm in the mood for some Ska. So without further ado, the Specials and Too Much Too Young.

---------

* Beumer W. et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology. August 2012.

** Kettenmann H. et al. Physiology of microglia. Physiological Reviews. 2011; 91: 461-553.

*** Hughes V. Microglia: the constant gardeners. Nature. 2012; 485: 570-572.

**** Morgan JT. et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biological Psychiatry. 2010; 68: 368-376.

***** Vargas DL. et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology. 2005; 57: 67-81.

****** MacFabe DF. et al. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behavioral Brain Research. 2007; 176: 149-169.

******* Schwarz JM. & Bilbo SD. Sex, glia, and development: Interactions in health and disease. Hormones & Behavior. February 2012.

---------

ResearchBlogging.org Beumer W, Gibney SM, & Drexhage RC (2012). The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes J Leukoc Biol. DOI: 10.1189/jlb.0212100

Friday, 17 August 2012

Vitamin D and autoimmunity and autism

Heavens above @ Paul Whiteley
They're at it again. The very marvellous Saudi-Egyptian autism research tag-team that is Gehan Mostafa and Laila Al-Ayadhi and another very, very interesting article titled: Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity* (full-text here).

I'd kinda been waiting for an article like this to come along given the shifting Eye of Sauron onto a possible role for the sunshine vitamin in cases of autism. You can find a little more background on the whole vitamin D-autism research base in a previous post I wrote some while back (here). I might also at this point plug a few other previous posts focused on vitamin D: leaky gut? (here), mental health and vitamin D deficiency? (here) and synthesis of vitamin D and the "evil" cholesterol (here). OK, stop with the self-promotion already.

The latest paper is full-text but to briefly summarise:

  • This wasn't just a study to see whether children with autism were deficient in vitamin D, or rather the active form of the vitamin, 25-hydroxy vitamin D, but rather also some inspection of any link between vitamin D levels and a feature of autoimmunity given the proposed immunological effects of vitamin D and the previously discussed suggestion of a link between autoimmunity and cases of autism.
  • Fifty children with autism (aged 5-12 years) were compared against 30 asymptomatic control children. Sunshine exposure data were collected, supplementation controlled for, and serum levels of 25-hydroxy vitamin D were ascertained during the spring/summer months (April-September).
  • Levels of anti-myelin-associated glycoprotein (anti-MAG) auto-antibodies were also measured in both groups. The presence of anti-MAG antibodies is basically a sign that the body is attacking myelin associated glycoproteins; myelin being an essential part of proper neuronal functioning. Elevations in anti-MAG antibodies is a sign that brain tissue is being targeted by the bodies own immune system.
  • The results: as a group, the children with autism presented with lower levels of 25-hydroxy vitamin D than controls (P<0.001), with about 40% of the autism group being classified as vitamin D deficient (<10ng/mL). None of the controls fell into the deficient range (although about 20% were classified as being 'insufficent' <30ng/mL). These results were based on pretty much equivalent sunshine exposure between the groups. There was also a suggestion of a negative correlation between 25-hydroxy vitamin D levels and scores on the CARS.
  • Children with autism as a group also presented with significantly higher levels of anti-MAG auto-antibodies compared to controls (P<0.001). Indeed increased levels were found in about 70% of participants with autism.
  • Serum 25-hydroxy vitamin D levels also significantly negatively correlated with anti-MAG auto-antibodies in children with autism.

Accepting that the participant groups were relatively small and the findings based on children I assume of Saudi origin, it is quite telling that children with autism living in a country where sunshine is probably not in short supply were still in the majority deficient in the active form of vitamin D. Appreciating the health advice that is provided nowadays when it comes to being 'sun aware' I still find some difficulty in accepting the fact that people in this region might not be getting enough sunshine to synthesise vitamin D as a way of accounting for the results. Could it be that autism, some cases of autism, confer problems with the biological synthesis and metabolism of vitamin D or even with the functioning of vitamin D receptors? If so, what are the implications for supplementation for example?

Anti-MAG antibodies is a new one for me in the autism research arena. Linked to a variety of autoimmune peripheral neuropathies, anti-MAG antibodies have actually been reported previously in cases of autism** (by the same authors). In that study, the authors introduced the possibility that "autism could be, in part, one of the pediatric autoimmune neuropsychiatric disorders". I'm not going to get too bogged down in the potential impact of anti-MAG antibodies and autism at this point though as more reading on my part is required.

So in short, a few more potential pointers for further investigations from the Saudi-Egyptian research team and another intriguing connection between vitamins and autism.  

To finish, I'm in the mood for a little Stranglers at the moment and a lovely tune called Gordon Brown... sorry, Golden Brown to at least remember what the sun looks like.

----------

* Mostafa G. & Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. Journal of Neuroinflammation. August 2012.

** Mostafa GA. et al. Serum anti-myelin—associated glycoprotein antibodies in Egyptian autistic children. Journal of Child Neurology. 2008; 23: 1413-1418.

---------

  ResearchBlogging.org
Mostafa G, & Al-Ayadhi L (2012). Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity Journal of Neuroinflammation
DOI: 10.1186/1742-2094-9-201